Selonabant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ANEB-001, V-24343) is a cannabinoid CB1 receptor antagonist which is under development for the treatment of acute cannabinoid intoxication. It was also previously being developed to treat obesity, but development for this indication was discontinued. The drug is administered by intravenous infusion. It dramatically reduced the subjective effects of Δ9-tetrahydrocannabinol (THC) in a clinical trial. Selonabant is being developed by Vernalis and Anebulo Pharmaceuticals. As of December 2024, it is in phase 2 trials.
See also Hallucinogen antidote
References